Drug Discovery

Can We Finally Target the Undruggable MYC Cancer Gene?
Research & Development Can We Finally Target the Undruggable MYC Cancer Gene?

The historical classification of the PVT1 locus as a non-coding region has been overturned by evidence showing it produces functional proteins that dictate the survival of malignant cells. For decades, the oncology community has viewed the MYC gene as the most frustrating obstacle in cancer

SandboxAQ Launches AQPotency to Accelerate Drug Discovery
Tech & Innovation SandboxAQ Launches AQPotency to Accelerate Drug Discovery

A major challenge in pharmaceutical development is the high failure rate of programs that stall because a target protein’s structure cannot be mapped. For many years, the pharmaceutical industry relied heavily on physical laboratory experiments that were both time-consuming and prone to human

Citius Pharmaceuticals Advances LYMPHIR Sales and Pipeline
Research & Development Citius Pharmaceuticals Advances LYMPHIR Sales and Pipeline

A record 383 vials of LYMPHIR were ordered in July, establishing a new performance benchmark for the company’s expanded 29-member nationwide sales infrastructure. This milestone represents a significant pivot for Citius Pharmaceuticals as it transitions from a clinical-stage entity into a

WuXi Biologics Leads Industry in Sustainable Biopharma Innovation
Management & Regulatory WuXi Biologics Leads Industry in Sustainable Biopharma Innovation

Securing an MSCI AAA ESG rating and an EcoVadis Platinum Medal places WuXi Biologics in the top 1% of companies evaluated for environmental and social governance. This landmark achievement underscores the organization's role as a dominant force in the global healthcare market, particularly as it

How Will AI Transform the Future of Drug Discovery?
Tech & Innovation How Will AI Transform the Future of Drug Discovery?

The pharmaceutical industry is currently witnessing a seismic transition that rivals the historical shift from basic alchemy to modern chemistry, as digital precision begins to replace the traditional reliance on serendipitous discovery. Closed-loop systems where AI predictions are immediately

Eli Lilly and Novo Nordisk Vie for GLP-1 Market Dominance
Management & Regulatory Eli Lilly and Novo Nordisk Vie for GLP-1 Market Dominance

Although 75 percent of the public believes weight-loss drugs are used for cosmetic reasons, 66 percent still find their use to be socially acceptable in modern society. This fundamental shift in perception coincides with the rise of glucagon-like peptide-1 receptor agonists, which have

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later